* Tearlab Corp says it has elected to pursue initial U.S. FDA clearance of a test card measuring a single inflammatory biomarker, MMP-9, in combination with co's osmolarity test * Tearlab - ‍ elected ...

SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”) today announced that it has submitted a 510(k) application to the U.S. Food and ...

Please provide your email address to receive an email when new articles are posted on . Boy, what a long road TearLab has traveled. It seems like I’ve been talking to them and about them forever.

SOUTHLAKE, Texas--(BUSINESS WIRE)--TearLab® Corporation, the global leader in ophthalmic point-of-care diagnostics, announced today that it will be expanding its position in corneal health under the ...

The company’s current osmolarity testing has been used over 24 million times, with primary growth driven in cornea and premium cataract/refractive practices Trukera Medical is positioned to expand its ...